Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis

Thumbnail
View/Open
Date
2019-05-01
Author
Rule, Simon cc
Dreyling, M
Goy, A
Hess, G
Auer, R
Kahl, B
Hernández-Rivas, J-Á
Qi, K
Deshpande, S
Parisi, L
Wang, M
Subject
Adenine
 
Clinical Trials as Topic
 
Drug Resistance, Neoplasm
 
Follow-Up Studies
 
Humans
 
Lymphoma, Mantle-Cell
 
Neoplasm Recurrence, Local
 
Piperidines
 
Prognosis
 
Pyrazoles
 
Pyrimidines
 
Salvage Therapy
 
Survival Rate
 

Metadata
Show full item record
Abstract

Copyright © 2018, Ferrata Storti Foundation.

URI
http://hdl.handle.net/10026.1/18912
DOI
Collections
Publisher
Ferrata Storti Foundation (Haematologica)
Place of Publication
Italy
Journal
Haematologica
Volume
104
Issue
5
Pagination
e211-e214
Author URL
Recommended, similar items

The following license files are associated with this item:

All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
PEARL Guides and Policies | PEARL Reports | Contact Us | Send Feedback | Admin Login
Theme by 
Atmire NV